SEC Form 4 · accession 0001179110-16-029281
MEDICINES CO /DE · MDCO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clive Meanwell
Officer — CEO · Director
Period of report
Aug 31, 2016
Accepted (ET)
Sep 2, 2016 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113481
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2016 | A | 378 | $28.08 | A | 339,168 | D | |
| Common Stock | Sep 1, 2016 | M | 1,377 | $28.60 | A | 340,545 | D | |
| Common StockF2 | Sep 1, 2016 | S | 1,377 | $40.00 | D | 339,168 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right-to-buy)F4,F3 | $28.60 | Sep 1, 2016 | M | 1,377 | D | — | Feb 16, 2017 | Common Stock | 1,377 | 68,623 | D |
Explanation of responses
- F1Acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning March 1, 2016 and ending August 31, 2016. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on March 1, 2016.
- F2Sales were effected pursuant to a Rule 10b-5 program adopted by Dr. Meanwell.
- F3This option vested in forty-eight equal installments beginning on March 16, 2007.
- F4Not applicable.